DNA vaccines for cervical cancer

Chien Fu Huang, Archana Monie, Wei Hung Weng, T. C. Wu

Research output: Contribution to journalReview articlepeer-review


Human papillomavirus (HPV), particularly type 16, has been associated with more than 99% of cervical cancers. There are two HPV oncogenic proteins, E6 and E7, which play a major role in the induction and maintenance of cellular transformation. Thus, immunotherapy targeting these proteins may be employed for the control of HPVassociated cervical lesions. Although the commercially available preventive HPV vaccines are highly efficient in preventing new HPV infection, they do not have therapeutic effects against established HPV infection or HPV-associated lesions. Since T cell-mediated immunity is important for treating established HPV infections and HPV-associated lesions, therapeutic HPV vaccine should aim at generating potent E6 and E7-specific T cell-mediated immune responses. DNA vaccines have now developed into a promising approach for antigen-specific T cell-mediated immunotherapy to combat infection and cancer. Because dendritic cells are the most potent professional antigenpresenting cells, and are highly effective in priming antigen-specific T cells, several DNA vaccines have employed innovative strategies to modify the properties of dendritic cells (DCs) for the enhancement of the DNA vaccine potency. These studies have revealed impressive pre-clinical data that has led to several ongoing HPV DNA vaccine clinical trials.

Original languageEnglish (US)
Pages (from-to)75-87
Number of pages13
JournalAmerican Journal of Translational Research
Issue number1
StatePublished - 2010


  • Cervical cancer
  • DNA vaccines
  • Human papillomavirus

ASJC Scopus subject areas

  • Molecular Medicine
  • Clinical Biochemistry
  • Cancer Research


Dive into the research topics of 'DNA vaccines for cervical cancer'. Together they form a unique fingerprint.

Cite this